TFEB and Duchenne muscular dystrophy: This regulatory capacity has made TFEB a key therapeutic target for several myopathic conditions, such as Pompe disease (Box 1), which is characterized by glycogen accumulation due to acid α-glucosidase deficiency, and Duchenne muscular dystrophy (DMD; Box 1), in which muscle atrophy results from autophagy dysregulation.